Search

Oncosil Medical

Unit 16, 589 Stirling Highway, COTTESLOE, 6011
08 9385 3552

Article Timeline

Notable People

NamePositionYear Started
Default
Tony King
Executive Consultant
Robert Hodby
Robert Hodby
Company Secretary2010
Roger Aston
Roger Aston
Non-Executive Director (Non-Executive Chair 2015-2017, Executive Chair 2013-2015)2013
David James
David James
Global Head of Manufacturing & Operations2015
Ash Soman
Ash Soman
Chief Medical Officer2015
Tom Milicevic
Tom Milicevic
Chief Financial Officer, Company Secretary2015
Daniel Kenny
Daniel Kenny
Chief Executive, Managing Director2015
Nicole Wilson
Nicole Wilson
Vice President, Regulatory Affairs & Quality2015
Chris Roberts
Chris Roberts
Non-Executive Chair2016
Michael Warrener
Michael Warrener
Director, Sales & Marketing2016
Martin Cross
Martin Cross
Non-Executive Director2017
* Most Senior WA Executive

Past Employees

NamePositionYear StartedYear Ended
Martin Rogers Non-Executive Director (Chair 2013-2014)20132016
Brian Leedman Co-Founder20132014
Bret Mattes Non-Executive Chairman20112013
Simon O'Loughlin Non-Executive Director20122013
Michael Robson Chairman02012
Neville Bassett Non-Executive Director20102012
Kyle Haynes Executive Director02012
Harry Karelis Non-Executive Chairman02011
David McAuliffe Executive Director20052010
Mark Treherne Executive Chairman20052010
Morgan Barron Company Secretary20082010
Chriss Moyses Non-Executive Director02009
Iain Chessell Chief Executive Officer02009
Narelle Warren Company Secretary20072009
Tony Evans Non-Executive Director20072009
John Hannaford Non-Executive Director20052009
Tony King Non-Executive Director20052007
Mark Bianchini Company Secretary02007
Narelle Lloyd Company Secretary2007
Alistair Dixon Executive Director20052006

Biography

Oncosil Medical, a neuroscience drug development company, operates in the life science sector in the United Kingdom and Australia. It engages in the development of compounds for the treatment of neuropathic pain. The company’s products under development include NSL-101, a natural product formulation for the treatment of pain, which has completed two Phase II clinical trials; and NSL-043, an oral product for neuropathic pain, which has completed two Phase I clinical trials. It has collaboration agreement with Sosei Corporation for developing NSL-043.
Biography last updated 04 Jun 2018

Share Transactions

04/04/13
$25k Bought
07/02/13
$30k Bought
05/07/12
$1k Bought
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer